ASCO: TALAPRO-1 phase II trial

TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC) – updated interim analysis (IA)

Abstract Number : 5566

Abstract Type : Poster Session

Indication : Metastatic Castration Resistant Prostate Cancer

Intervention : Talazoparib

Company : Pfizer

Technology : Small molecule


113 pts received TALA (cutoff Dec 12, 2019); 75 pts were DDRp, had measurable disease, received $16 wk treatment, and were evaluable for ORR (54.7% BRCA1/2, 4.0% PALB2, 22.7% ATM; 18.7% other DDRm).All DDRp pts had prior docetaxel; 45.3% cabazitaxel. Confirmed ORR, rPFS, and composite response (investigator-assessed) in pts who received TALA for $16 weeks are in the table. Most common treatment-emergent adverse events: anemia (42.5%); nausea (32.7%).


TALA monotherapy has encouraging antitumor activity in docetaxel-pretreated mCRPC pts with BRCA1/2 alterations and was generally well tolerated.


In this interim analysis of TALAPRO-1, talazoparib monotherapy demonstrated anti-tumor activity in mCRPC patients with DDR alteration who have previously received taxane chemotherapy and next-generation hormonal therapy with a conformed overall response rate of 25.6%

Refer to Metastatic Castration Resistant Prostate Cancer Market report for detailed Insights.